pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 40 Non-oncology: 27
Oncology: 13
Under Consideration for Negotiation 18 Non-oncology: 10
Oncology: 8
Completed Negotiations 840 With Letter of Intent: 730
Without agreement: 110
Negotiations That Were Not Pursued 111

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Opdivo SC Bristol Myers Squibb Canada Inc. Multiple Indications
Methofill Accord Healthcare Inc. Multiple Indications
Nordimet Nordic Pharma Multiple Indications
Skyclarys Biogen Canada Inc. Friedreich’s ataxia
Ferinject CSL Vifor Iron Deficiency Anemia
Ferinject CSL Vifor Iron deficiency in adult patients with heart failure
Iqirvo Ipsen Biopharmaceuticals Canada, Inc. Primary biliary cholangitis
Sogroya Novo Nordisk Canada Inc. Growth hormone deficiency
Omnipod 5 Insulet Canada Corporation Patients with Type 1 Diabetes aged 2 years and old
Camcevi Accord Healthcare Inc. For the treatment of adult patients with advanced prostate cancer

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Opdivo Bristol Myers Squibb Canada Inc. ​With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.
Osdenza Apotex Inc. Osteoporosis
Idenos Apotex Inc. Multiple Indications
Rystiggo UCB Canada Inc. Generalized myasthenia gravis (gMG)
Zilbrysq UCB Canada Inc. Generalized myasthenia gravis (gMG)
Bildyos Organon Canada Inc. Multiple Indications
Ebglyss Eli Lilly Canada Inc. Atopic dermatitis
To be Confirmed Organon Canada Inc. Multiple Indications
Avtozma Celltrion Healthcare Canada Ltd. Multiple Indications
Aflivu Apotex Inc. Multiple Indications
TBC Sandoz Canada Inc. Multiple Indications
Yesafili Biocon Biologics Canada Inc. Multiple Indications
TBC (aflibercept) Organon Canada Inc. Multiple Indications
Eydenzelt Celltrion Healthcare Canada Ltd. Multiple Indications
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia (non-familial and heterozygous familial)
Balversa Janssen Inc. Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior th
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Voydeya Alexion Pharma GmbH Paroxysmal nocturnal hemoglobinuria (PNH)

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks